Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Anyone else not able to view on WealthSimple?

<< Previous

Bullboard Posts

Next >>

Comment by stocksarefunon Dec 17, 2020 10:03am

78 Views

Post# 32127308

RE:RE:Anyone else not able to view on WealthSimple?

can't figure out how to post a screenshot but the message was that the security was inactive yesterday all day. News about halt was Tuesday, no?

Here's what the message said.

THERE'S BEEN A CHANGE IN THIS SECURITY

The security is now inactive due to a corporate action, merger, stock split or an acquisition. Our clearing broker is updating the security to reflect this change. This process typically takes 3-5 business days. Until then, you won't be able to trade your current holdings of this security. If you believe this is incorrect, please reach out to support

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading